Cytadren, aminoglutethimide tablets USP, is an inhibitor of adrenocortical steroid synthesis, available as 250-mg tablets for oral administration.
Cytadren is indicated for the suppression of adrenal function in selected patients with Cushing’s syndrome. Morning levels of plasma cortisol in patients with adrenal carcinoma and ectopic ACTH-producing tumors were reduced on the average to about one half of the pretreatment levels, and in patients with adrenal hyperplasia to about two thirds of the pretreatment levels, during 1-3 months of therapy with Cytadren. Data available from the few patients with adrenal adenoma suggest similar reductions in plasma cortisol levels. Measurements of plasma cortisol showed reductions to at least 50% of baseline or to normal levels in one third or more of the patients studied, depending on diagnostic groups and time of measurement.
Because Cytadren does not affect the underlying disease process, it is used primarily as an interim measure until more definitive therapy such as surgery can be undertaken or in cases where such therapy is not appropriate. Only small numbers of patients have been treated for longer than 3 months. A decreased effect or “escape phenomenon” seems to occur more frequently in patients with pituitary-dependent Cushing’s syndrome, probably because of increasing ACTH levels in response to decreasing glucocorticoid levels.
Cytadren should be used only in those patients who are responsive to treatment.
Published Studies Related to Cytadren (Aminoglutethimide)
Aminoglutethimide but not spironolactone enhances the anticonvulsant effect of some antiepileptics against amygdala-kindled seizures in rats. [2005.07]
Aminoglutethimide (AGLD, an inhibitor of adrenal steroid synthesis) up to 5 mg/kg and spironolactone (SPIR, a mineralocorticosteroid antagonist and a weak antiandrogen) up to 50 mg/kg did not affect any seizure parameter in amygdala-kindled rats.Moreover, extrapolation of obtained results to clinical practice may indicate that patients with complex partial seizures may be safely co-medicated with AGLD or SPIR without the risk of worsening of seizure control.
Influence of aminoglutethimide and spironolactone on the efficacy of carbamazepine and diphenylhydantoin against amygdala-kindled seizures in rats. [2005.06.15]
Antagonists of steroid receptors may interfere with seizure phenomena. The present study deals with effects of aminoglutethimide and spironolactone on the action of carbamazepine and diphenylhydantoin in amygdala-kindled rats of both genders... In conclusion, our results suggest that doses of carbamazepine and diphenylhydantoin should be modified in epileptic patients concomitantly treated with aminoglutethimide or spironolactone.
Clinical Trials Related to Cytadren (Aminoglutethimide)
Randomized Study Comparing Tamoxifen Vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-Positive Patients [Completed]
Primarily, this clinical investigation compared the efficacy of tamoxifen + aminoglutethimide
vs. tamoxifen alone in terms of prognosis (overall survival) in postmenopausal patients with
potentially curative, operated hormone receptor-positive breast cancer.
Hydrocortisone Plus Aminoglutethimide or Ketoconazole in Treating Patients With Localized Stage IV Prostate Cancer [Active, not recruiting]
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as
aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones.
Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective
treatment for prostate cancer.
PURPOSE: Phase II trial to study the effectiveness of combining hydrocortisone with either
aminoglutethimide or ketoconazole in treating patients who have localized stage IV prostate
Page last updated: 2006-01-31